These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1697448)

  • 61. Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between Org 10172 and dextran 70.
    Bergqvist D; Kettunen K; Fredin H; Faunø P; Suomalainen O; Soimakallio S; Karjalainen P; Cederholm C; Jensen LJ; Justesen T
    Surgery; 1991 May; 109(5):617-22. PubMed ID: 1708528
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis.
    Cade JF; Wood M; Magnani HN; Westlake GW
    Thromb Res; 1987 Mar; 45(5):497-503. PubMed ID: 3590088
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Orgaran in hip fracture surgery.
    Bergqvist D
    Haemostasis; 1992; 22(2):104-8. PubMed ID: 1379963
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
    Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
    Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
    [No Abstract]   [Full Text] [Related]  

  • 65. Thrombosis prophylaxis in an AT III deficient pregnant woman: application of a low molecular weight heparinoid.
    Henny CP; ten Cate H; ten Cate JW; Prummel MF; Peters M; Büller HR
    Thromb Haemost; 1986 Apr; 55(2):301. PubMed ID: 3715796
    [No Abstract]   [Full Text] [Related]  

  • 66. Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers.
    de Boer A; Stiekema JC; Danhof M; Moolenaar AJ; Breimer DD
    Eur J Clin Pharmacol; 1991; 41(3):245-50. PubMed ID: 1748141
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Partial in vivo neutralisation of plasma anticoagulant effects of Lomoparan (Org 10172) by protamine chloride.
    Stiekema JC; Wijnand HP; ten Cate H; ten Cate JW; Harenberg J; Egberts JF; van Dinther TG
    Thromb Res; 1991 Jul; 63(1):157-67. PubMed ID: 1948817
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Determination of low molecular weight heparin in clinical laboratory.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):205-10. PubMed ID: 6203817
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans.
    Vogel GM; Meuleman DG; Bourgondiën FG; Hobbelen PM
    Thromb Res; 1989 Jun; 54(5):399-410. PubMed ID: 2549654
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Placental transfer of Org 10172, a low-molecular weight heparinoid, in the awake late-pregnant guinea pig.
    Peeters LL; Hobbelen PM; Verkeste CM; Vogel GM; Hasenack HG; Meuleman DG; Wallenburg HC
    Thromb Res; 1986 Nov; 44(3):277-83. PubMed ID: 3798400
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers.
    de Boer A; Stiekema JC; Danhof M; van Dinther TG; Boeijinga JK; Cohen AF; Breimer DD
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2110-5. PubMed ID: 1759835
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Differences between anterior and posterior circulation stroke in TOAST.
    Libman RB; Kwiatkowski TG; Hansen MD; Clarke WR; Woolson RF; Adams HP
    Cerebrovasc Dis; 2001; 11(4):311-6. PubMed ID: 11385210
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke. The program developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
    Albanese MA; Clarke WR; Adams HP; Woolson RF
    Stroke; 1994 Sep; 25(9):1746-51. PubMed ID: 8073453
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Anti-factor Xa monitoring of anticoagulation during cardiopulmonary bypass in a patient with antiphospholipid syndrome.
    Lennon MJ; Thackray NM; Gibbs NM
    Anaesth Intensive Care; 2003 Feb; 31(1):95-8. PubMed ID: 12635404
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Development of non-heparin glycosaminoglycans as therapeutic agents: II. A symposium. Chicago.
    Semin Thromb Hemost; 1991; 17 Suppl 2():137-245. PubMed ID: 1683007
    [No Abstract]   [Full Text] [Related]  

  • 76. [Heparinoid substances. I. Value of Allen's protamine sulfate titration as routine method in x-ray exposure].
    DE VRIES SI; VAN DAELEN CC
    Ned Tijdschr Geneeskd; 1954 Oct; 98(43):3051-6. PubMed ID: 13223836
    [No Abstract]   [Full Text] [Related]  

  • 77. Anticoagulation for cardiopulmonary bypass, Part 2: alternatives and pathological states.
    Cartwright B; Mundell N
    BJA Educ; 2023 Jul; 23(7):256-263. PubMed ID: 37389280
    [No Abstract]   [Full Text] [Related]  

  • 78. Anticoagulant therapy during cardiopulmonary bypass.
    Yavari M; Becker RC
    J Thromb Thrombolysis; 2008 Dec; 26(3):218-28. PubMed ID: 18931979
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Thrombin inhibitors and cardiopulmonary bypass.
    Merry A
    J Extra Corpor Technol; 2006 Mar; 38(1):52-6. PubMed ID: 16637526
    [No Abstract]   [Full Text] [Related]  

  • 80. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.